Effect of the long-term treatment with trandolapril on endoglin expression in rats with experimental renal fibrosis induced by renal mass reduction

Kidney and Blood Pressure Research

Volumn 28, Issue 1, 2005, Pages 32-40

  Prieto, Marta ^a   Rodríguez Peña, Ana ^a   Arévalo, Miguel ^a   Rivas, Juan V ^a   Düwel, Annette ^a   Eleno, Nélida ^a   Sánchez, Rafael J ^a   Morales, Ana I ^a   López Novoa, José M ^a   Pérez Barriocanal, Fernando ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Angiotensin; Endoglin; Fibrosis; Kidney, rat; Renal mass reduction; Trandolapril

Indexed keywords

COLLAGEN TYPE 2; COLLAGEN TYPE 4; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOGLIN; MEMBRANE PROTEIN; TRANDOLAPRIL; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; GLOMERULOPATHY; IMMUNOHISTOCHEMISTRY; KIDNEY FIBROSIS; KIDNEY FUNCTION TEST; LONG TERM CARE; MALE; MEAN ARTERIAL PRESSURE; NEPHRECTOMY; NONHUMAN; NORTHERN BLOTTING; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; QUANTITATIVE ANALYSIS; RAT; REGULATORY MECHANISM; URINARY EXCRETION;

EID: 19944427099     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081439     Document Type: Article

References (39)

1. Klahr S, Schreiner G, Ichikawa I: The progression of renal disease. N Engl J Med 1988;318:1657-1666.
2. Neuringer JR, Brenner BM: Hemodynamic theory of progressive renal disease: A 10-year update in brief review. Am J Kidney Dis 1993;22:98-104.
3. Lafayette RA, Mayer G, Park SK, Meyer TW: Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 1992;90:766-771.
4. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Molotese M, Ponticelli C, Ritz E, Zucchelli P: The angiotensin-converting-enzyme inhibition in progressive renal insufficiency study group: Effect of the angiotensinconverting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996;334:939-945.
5. Anderson S, Rennke HG, Brenner BM: Therapeutic advantages of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986;77:1993-2000.
6. Remuzzi A, Puntorieri S, Battaglia C, Bertani T, Remuzzi G: Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rats. J Clin Invest 1990;85:541-549.
7. Rodríguez-Peña A, Prieto M, Duwel A, Rivas JV, Eleno N, Pérez-Barriocanal F, Arévalo M, Smith JD, Vary CPH, Bernabéu C, López-Novoa JM: Up-regulation of endoglin, a TGF-β-binding protein, in rats with experimental renal fibrosis induced by renal mass reduction. Nephrol Dial Transplant 2001;16:34-39.
8. Border WA, Noble NA: Transforming growth factor β in tissue fibrosis. N Engl J Med 1994;331:1286-1292.
9. Okuda S, Languino LR, Ruoslahti E, Border WA: Elevated expression of transforming growth factor-β and proteoglycan production in experimental glomerulonephritis: Possible role in expansion of the mesangial extracellular matrix. J Clin Invest 1990;86:453-462.
10. Tamaki K, Okuda S, Ando T, Iwamoto T, Nakayama M, Fujishima M: TGF-β1 in glomerulosclerosis and interstitial fibrosis of adriamycin nephropathy. Kidney Int 1994;45:525-536.
11. Egido J: Vasoactive hormones and renal sclerosis. Kidney Int 1996;49:578-597.
12. Kagami S, Border WA, Miller DE, Noble NA: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest 1994;93:2431-2437.
13. Gougos A, Letarte M: Identification of a human endothelial cell antigen with monoclonal antibody 44C4 produced against a pre-B leukemic cell line. J Immunol 1988;141:1925-1933.
14. Lastres P, Bellón T, Cabañas C, Sánchez-Madrid F, Acevedo A, Gougos A, Letarte M, Bernabéu C: Regulated expression on human macrophages of endoglin, an Arg-Cly-Asp-containing surface antigen. Eur J Immunol 1992;22:393-397.
15. Gougos A, St Jacques S, Creaves A, O'Connell PJ, d'Apice AJF, Bohring HJ, Bernabéu C, van Mourik JA, Letarte M: Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells leukemic cells, and syncytiotrophoblasts. Int Immunol 1992;4:83-92.
16. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, Helmbold EA, Markel DS, McKinnon WC, Murrell J, MacCormick MK, Perick-Vance MA, Heutink P, Oostra BA, Haitjema T, Westerman CJJ, Porteus ME, Guttmacher AE, Letarte M, Marchuk DA: Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994;8:345-351.
17. Cheifetz S, Bellón T, Scalés C, Vera S, Bernabéu C, Massagué J, Letarte M: Endoglin is a component of the transforming growth factor-β receptor system in human endothelial cells. J Biol Chem 1992;267:19027-19030.
18. Roy-Chaudhury P, Simpson JG, Power DA: Endoglin, a transforming growth factor-betabinding protein, is upregulated in chronic progressive renal disease. Exp Nephrol 1997;5:55-60.
19. Lastres P, Letamendía A, Zhang H, Rius C, Almendro N, Raab U, López LA, Langa C, Fabra A, Letarte M, Bernabéu C: Endoglin modulates cellular responses to TGF-β1. J Cell Biol 1996;13:1109-1121.
20. Letamendía A, Lastres A, Botella LM, Raab U, Langa C, Velasco B, Attisano L, Bernabéu C: Role of endoglin in cellular responses to transforming growth factor β. A comparative study with betaglycan. J Biol Chem 1998;273:33011-33019.
21. Diez-Marques L, Ortega-Velazquez R, Langa C, Rodríguez-Barbero A, López-Novoa JM, Lamas S, Bernabéu C: Expression of endoglin in human mesangial cells: modulation of extracellular matrix synthesis. Biochim Biophys Acta 2002;1587:36-44.
22. Bosnes RW, Tausski HA: The colorimetric determination of creatinine of the Jaffé reaction. J Biol Chem 1945;158:581-583.
23. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
24. Flores O, Arévalo M, Gallego B, Hidalgo F, Vidal S, López-Novoa JM: Beneficial effect of the long-term treatment with the combination of an ACE inhibitor and a calcium channel blocker on renal injury in rats with 5/6 nephrectomy. Exp Nephrol 1998;6:39-49.
25. Chomczynski P, Sacci N: Single-step method for RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
26. Ichikawa I, Iko M, Fogo A: Glomerular growth factors, the common key mediators for progressive glomerular sclerosis in chronic renal disease. Adv Nephrol 1991;20:127-148.
27. Wu LL, Cox A, Roe CJ, Dziadek M, Cooper ME, Gilbert RE: Transforming growth factor-β1 and renal injury following subtotal nephrectomy in the rat: Role of the renin-angiotensin system. Kidney Int 1997;51:1553-1567.
28. Border WA, Noble N: Transforming growth factor beta in glomerular injury. Exp Nephrol 1994;2:13-17.
29. Yamamoto T, Noble NA, Miller DE, Border WA: Sustained expression of TGF-β underlies development of progressive kidney fibrosis. Kidney Int 1994;45:916-927.
30. Gilbert RE, Wu LL, Kelly DJ, Cox A, Wilkinson-Berka JL, Johnston CI, Cooper ME: Pathological expression of renin and angiotensin II in the renal tubule after subtotal nephrectomy. Implications for the pathogenesis of tubulointerstitial fibrosis. Am J Pathol 1999;155:429-440.
31. Rodríguez-Peña A, Eleno N, Düwell A, Arévalo M, Pérez-Barriocanal F, Flores O, Docherty N, Bernabéu C, Letarte M, López-Novoa JM: Endoglin upregulation during experimental renal interstitial fibrosis in mice. Hypertension 2002;40:713-720.
32. Border WA, Noble N: Cytokines in kidney disease: The role of transforming growth factor beta. Am J Kidney Dis 1993;22:105-113.
33. Conley BA, Smith JD, Guerrero-Esteo M, Bernabéu C, Vary CPH: Endoglin, a TGF-beta binding protein, is expressed by smooth muscle cells in human atherosclerotic plaques. Atherosclerosis 2000;153:323-335.
34. Rodríguez Barbero A, Obreo J, Yuste L, Montero JC, Rodríguez-Peña A, Pandiella A, Bernabéu C, López-Novoa JM: Transforming growth factor-β1 induces collagen synthesis and accumulation via p38 mitogen-activated protein kinase (MAPK) pathway in cultured L6E9 myoblasts. FEBS Lett 2002;513:282-288.
35. Li D, Chen H, Mehta JL: Angiotensin II via activation of type 1 receptor upregulates expression of endoglin in human coronary artery endothelial cells. Hypertension 2001;38:1062-1067.
36. Klahr S, Morrissey J: Progression of chronic renal disease. Am J Kidney Dis 2003;41:S3-S7.
37. Motojima M, Kakuchi J, Yoshioka T: Association of TGF-β signalling in angiotensin IIinduced PAI-1 mRNA upregulation in mesangial cells. Role of PKC. Biochim Biophys Acta 1999;1449:217-226.
38. Fukuda N, Hu WY, Kubo A, Kishioka H, Satoh C, Soma M, Izumi Y, Kanmatsuse K: Angiotensin II upregulates transforming growth factor type 1 receptor on rat vascular smooth muscle cells. Am J Hypertens 2000;13:191-198.
39. Rodríguez-Barbero A, Obreo J, Eleno N, Rodríguez-Pena A, Duwel A, Jerkic M, Sánchez-Rodríguez A, Bernabéu C, López-Novoa JM: Endoglin expression in human and rat mesangial cells and its upregulation by TGF-beta1. Biochem Biophys Res Commun 2001;282:142-147.